Real World Study on the Use of Cemiplimab in Adult Patients in UK (REACT-CEMI)

Sanofi

Status: Completed

Conditions: Cutaneous Squamous Cell Carcinoma

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT05493826

DUT0052

Details and patient eligibility

About

The primary objective is to describe the real-world clinical effectiveness of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) or metastatic cutaneous squamous cell carcinoma (mCSCC) treated in routine clinical practice.

Full description

Patients initiating treatment with cemiplimab in the UK between 2nd July 2019 and 30th November 2020, will be followed for a minimum of 12 and a maximum of 36 months from initiation of cemiplimab.

Enrollment: 110 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged >=18 years at initiation of cemiplimab.
• Patients treated with >=1 dose of cemiplimab for laCSCC or mCSCC who were not suitable for curative surgery or curative radiation according to routine practice.
• Patients initiating treatment with cemiplimab in the UK between 2nd July 2019 and 30th November 2020.

Exclusion criteria

• Patients who are known to have opted out of participation in any research (as required for compliance with GDPR).
• Patients participating in any form of investigative study (e.g., clinical trials) during the post-index observation period.

Trial design

110 participants in 1 patient group

Group 1

Description:

Patients treated with cemiplimab for laCSCC or mCSCC who were not suitable for curative surgery or curative radiation

Treatment:

Other: No intervention